In support of the report that IL-5 and IL-13 antibodies, such as mepolizumab and lebrikizumab, respectively, demonstrated certain clinical efficacy in a subset of patients with asthma [31, 32], our findings suggested that anti-Dectin-2 MoAbs can be potential therapeutics for mite-mediated allergic diseases via blocking IL-5 and IL-13 production. This evidence concerns the gene IL13 and asthma.